Dr Pramod Kumar Pandey, PhD in Chemistry, is a Analytical expert with 31+ years of experience in pharmaceutical development and the founder of PharmaGuru.co, a global platform for pharmaceutical training and industry insights
Reporting Pharmaceutical Impurities is essential for ensuring drug safety, quality, and regulatory compliance. Learn ICH guidelines, reporting thresholds, quantification limits, and best practices for accurate impurity analysis in pharmaceuticals.
Reporting Pharmaceutical Impurities: A Practical Case Study on Accurate Data Interpretation
Image created in Bing
Reporting Pharmaceutical Impurities is a critical, highly regulated process that ensures the safety, quality, and efficacy of drug products. In line with guidelines from the International Council for Harmonisation, impurity reporting involves the identification and quantification of unwanted chemical substances that may arise from synthesis, degradation, or interactions during manufacturing and storage.
These impurities must be reported at defined thresholds, typically starting from the quantification limit (QL) or the reporting threshold—commonly around 0.05% or 0.1%, depending on the maximum daily dose of the drug. Accurate impurity reporting is essential for regulatory compliance, risk assessment, and ensuring patient safety throughout the product lifecycle.
Reporting Pharmaceutical Impurities: A Practical Case Study on Accurate Data Interpretation
In addition to the specification/limit, the detection limit (DL) of impurities, the quantification limit (QL) must also be considered when reporting pharmaceutical impurity results. Impurity data should be presented in a clear, structured, and accurate manner to ensure regulatory compliance and data integrity
Expert Tips
Don’t integrate the impurity peaks having a value less than DL (detection limit)
Integrate the impurity peaks having a value more than or equal to the DL (detection limit)
Impurities having a value less than or equal to QL (quantification) should not be included in the total impurities
Impurities having a value more than or equal to QL (quantification) should be included in the total impurities
Case Study: Certificate of Analysis (CoA)-Impurities Section
Product Name: [e.g., Paracetamol] Batch Number: [e.g., ab123] Date of Analysis: [e.g., 18-06-2025] Test Method Reference: [e.g., In-house HPLC Method No. xyz]
Impurity Name
Limit (% w/w)
Impurities Result in Chromatogram
Reporting Result in COA
Impurity A
NMT 0.10%
0.07%
0.07%
Impurity B
NMT 0.15%
0.02%
<QL (QL = 0.03%)
Impurity C
NMT 0.10%
0.005%
<DL (DL = 0.01%)
Any Unknown Unspecified Impurity
NMT 0.10%
0.04%
0.03%
Total Impurities
NMT 0.60%
0.14%
0.10%
Note:
DL = 0.01%
QL = 0.03%
Expert Tips:
Results should differentiate known and unknown impurities.
Use validated analytical methods.
Ensure alignment with pharmacopoeial or internal specifications.
If reporting to regulatory bodies, specify identification thresholds, reporting thresholds (RL), and qualification thresholds per ICH guidelines.
How do you ensure the accuracy and repeatability of the test results?
In pharmaceutical analysis, accuracy and repeatability are ensured by:
Using validated analytical methods following ICH or pharmacopeial guidelines.
Calibrating instruments regularly with certified reference standards.
Following Good Laboratory Practices (GLP) and Standard Operating Procedures (SOPs).
Running system suitability tests before sample analysis.
Performing replicate analyses and calculating %RSD (relative standard deviation) to assess repeatability.
Using quality control samples and known standards to verify accuracy.
Maintaining consistent environmental conditions and proper documentation throughout the process.
